Abbott delivered aligned first-quarter results with steady earnings and achieved a key strategic milestone with the acquisition of Exact Sciences, enhancing its diagnostics leadership and growth prospects.
- Adjusted EPS of $1.15 met guidance despite headwinds from early financing costs and a weaker respiratory season.
- Completed the Exact Sciences acquisition, adding ~$3 billion in expected 2026 sales and accelerating long-term growth trajectory.
- Diagnostics sales grew 2%, with Core Lab up 3%, while Molecular Diagnostics declined 10% due to weaker respiratory testing demand.
- Cancer Diagnostics posted 13% growth driven by strong international performance and Cologuard.
- Medical Devices revenue increased 8.5%, led by robust cardiovascular product sales, supported by pipeline advancements and clinical trial initiatives.
Community Discussion